Mechanistically, no significant differences in tumor-infiltrating lymphocytes, PD-L1 levels, or gene-expression profiles that are typically associated with CDK4/6 inhibitor resistance were observed between patients who showed a complete response versus those who did not [177]. This evidence concerns the gene CDK4 and neoplasm.